Phase II Trial of CC-5013 (Lenalidomide, Revlimid) in Patients With Cutaneous T-Cell Lymphoma.

Trial Profile

Phase II Trial of CC-5013 (Lenalidomide, Revlimid) in Patients With Cutaneous T-Cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2018

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Mycosis fungoides; Sezary syndrome
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 24 Jan 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2020.
    • 24 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 05 May 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top